Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Total Liabilities for 7 consecutive years, with $163.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 14.56% to $163.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $163.1 million, a 14.56% increase, with the full-year FY2025 number at $163.1 million, up 14.56% from a year prior.
  • Total Liabilities was $163.1 million for Q4 2025 at Kymera Therapeutics, up from $155.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $189.3 million in Q1 2021 to a low of $113.0 million in Q4 2022.
  • A 5-year average of $149.9 million and a median of $149.2 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 101.81% in 2021, then dropped 29.04% in 2022.
  • Kymera Therapeutics' Total Liabilities stood at $146.3 million in 2021, then dropped by 22.76% to $113.0 million in 2022, then skyrocketed by 60.01% to $180.8 million in 2023, then dropped by 21.22% to $142.4 million in 2024, then increased by 14.56% to $163.1 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Total Liabilities are $163.1 million (Q4 2025), $155.8 million (Q3 2025), and $159.6 million (Q2 2025).